Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-12-21
2009-12-29
Seaman, D. Margaret (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S114000
Reexamination Certificate
active
07638519
ABSTRACT:
The present invention provides certain compounds, pharmaceutical formulations thereof, and methods for the treatment of conditions mediated by 5-HT2 receptors. These compounds provide for modulation of the signals mediated by 5-HT2 receptors, specifically those receptors in the cardiovascular system. Thus, these compounds may be used alone or in conjunction with other drugs to treat cardiovascular diseases such as, but not limited to, muscle atrophy, cardiac hypertrophy, heart failure, and primary pulmonary hypertension.
REFERENCES:
patent: 5093493 (1992-03-01), Thompson et al.
patent: 6974870 (2005-12-01), Cywin et al.
patent: 7119102 (2006-10-01), Chen et al.
patent: WO 2006/103511 (2006-10-01), None
patent: WO 2006/122944 (2006-11-01), None
patent: WO 2006/125812 (2006-11-01), None
Bush et al., “A small molecular activator of cardiac hypertrophy uncovered in a chemical screen for modifiers of the calcineurin signaling pathway,”Proc. Natl. Acad. Sci. USA, 101:2870-2875, 2004.
Kireev et al., “Molecular modeling and quantitative structure-activity studies of anti-HIV-1 2-heteroarylquinoline-4-amines,”Eur. J. Med. Chem., 30:395-402.
Ming et al., “Heterocondensed Pyridines by Cycloaddition-Extrusion Sequence of Bi- and Tricyclic 1,3-Oxaziones with N,N-Diethyl-1-propynylamine,”Chem. Ber., 120:1427-1431, 1987.
Pinard et al., “4-Aminoquinolines as a Novel Class of NR1/2B Subtype Selective NMDA Receptor Antagonists,”Bioorganic&Med. Chem. Lett., 12:2615-2619, 2002.
Strekowski et al., “Synthesis and Quantitative Structure-Activity Relationship Analysis of 2-(Aryl or Heteroaryl)quinolin-4-amines, a New Class of Anti-HIV-1 Agents,”J. Med. Chem., 34:1739-1746, 1991.
Valenti et al., “Acetylcholinesterase inhibition by tacrine analogues,”Bioorg.&Med. Chem. Lett., 7:2599-2602, 1997.
Al-Omran, “Aynthesis and biological effects of new derivatives of benzotriazole as antimicrobial and antifungal agents,”J. Heterocyclic Chem., 39:877-883, 2002.
Casnati et al., “Some synthetic applications of the reaction of reductive opening of the isoxazole ring,”Tet. Lett., 233-238, 1966.
Gewald et al., “Synthesen von 4-amino-thieno[2,3—b]pyridinen,”Monatshefte fur Chemie, 110:1189-1196, 1979.
Kandeel, “Nitriles in heterocyclic synthesis: a novel synthesis of some thieno[2,3-d]primidine and thieno[2,3-b]pridine derivatives,”Heteroatom Chemistry, 7:29-33, 1966.
Mohareb et al., “Synthetic potentialities of thiophene systems in heterocyclic synthesis: a novel synthesis of thieno[2,3-b]pyridine derivatives,”Phosphorous, Sulfur and Silicon and the Related Elements, 155:215-233, 1999.
Strekowski et al., “A facile synthesis of 2-aryl- and 2-heteroaryl-substituted 4- aminoquinolines,”Heterocycles, 29:539-545, 1989.
Strekowski et al., “Synthesis of 2,2,4-trisubstituted-1,2-dihydroquinazolines,”J. Heterocyclic Chem., 26:923-928, 1989.
Strekowski et al., “Synthesis of bis(2-arylquinolin-4-yl)amines by lithium bis(trimenthylsilyl)amide-mediated cyclization of ketimines derived from 2-(trifluoromethy)anilines and aryl methyl ketones,”J. Org. Chem., 62:4193-4196, 1997.
Thomsen and Torssell, “Synthesis of simple quinoline alkaloids. A novel quinazoline synthesis,”Acta Chimica Scandinavica, Series B: Organic Chemistry and Biochemistry, B42:309-313, 1988.
Young et al.,Handbook of Applied Therapeutics, 7.1-7.12 and 9.1-9.10, 1989.
Fitzgerald et al., “Possible role of valvular serotonin 5-HT2B receptors in the cardiopathy associated with fenfluramine,”Molecular Pharmacology, 57:75-81, 2000.
Knowles and Ramage, “Evidence for a role for central 5-HT2Bas well as 5-HT2Areceptors in cardiovascular regulation in anaesthetized rates,”British Journal of Pharmacology, 128:530-542, 1999.
Ogawa et al., “Pharmacological profiles of R-96544, the active form of a novel 5-HT2Areceptor antagonist R-102444,”European Journal of Pharmacology, 457:107-114, 2002.
Villalón et al., “Serotonin receptors as cardiovascular targets,”Drug Discov. Today, 2(7):294-300, 1997.
Office Communication issued in European Application No. EP04815043, dated Feb. 29, 2008.
Frishman et al., “Serotonin and serotonin antagonism in cardiovascular and non-cardiovascular disease,”J. Clin. Pharmacol., 35:541-572, 1995.
Bush Erik
Melvin Larry
Fulbright & Jaworski
Myogen, Inc.
Seaman D. Margaret
LandOfFree
Compounds, pharmaceutical compositions, and methods for the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds, pharmaceutical compositions, and methods for the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds, pharmaceutical compositions, and methods for the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4070540